Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 293

1.

Corrigendum to "Pharmacokinetic simulations to explore dissolution criteria of BCS I and III biowaivers with and without MDR-1 efflux transporter" [European Journal of Pharmaceutical Sciences Volume 61, 30 September 2014, Pages 18-26].

Kortejärvi H, Malkki J, Shawahna R, Scherrmann JM, Urtti A, Yliperttula M.

Eur J Pharm Sci. 2019 Apr 1;131:254. doi: 10.1016/j.ejps.2019.03.004. No abstract available.

PMID:
30850072
2.

LC-MS/MS-based quantification of efflux transporter proteins at the BBB.

Gomez-Zepeda D, Taghi M, Smirnova M, Sergent P, Liu WQ, Chhuon C, Vidal M, Picard M, Thioulouse E, Broutin I, Guerrera IC, Scherrmann JM, Parmentier Y, Decleves X, Menet MC.

J Pharm Biomed Anal. 2019 Feb 5;164:496-508. doi: 10.1016/j.jpba.2018.11.013. Epub 2018 Nov 8.

PMID:
30453156
3.

Integrated Pharmacokinetic/Pharmacodynamic Model of a Bispecific CD3xCD123 DART Molecule in Nonhuman Primates: Evaluation of Activity and Impact of Immunogenicity.

Campagne O, Delmas A, Fouliard S, Chenel M, Chichili GR, Li H, Alderson R, Scherrmann JM, Mager DE.

Clin Cancer Res. 2018 Jun 1;24(11):2631-2641. doi: 10.1158/1078-0432.CCR-17-2265. Epub 2018 Feb 20.

4.

Expression and function of Abcg4 in the mouse blood-brain barrier: role in restricting the brain entry of amyloid-β peptide.

Dodacki A, Wortman M, Saubaméa B, Chasseigneaux S, Nicolic S, Prince N, Lochus M, Raveu AL, Declèves X, Scherrmann JM, Patel SB, Bourasset F.

Sci Rep. 2017 Oct 17;7(1):13393. doi: 10.1038/s41598-017-13750-0.

5.

Targeted unlabeled multiple reaction monitoring analysis of cell markers for the study of sample heterogeneity in isolated rat brain cortical microvessels.

Gomez-Zepeda D, Chaves C, Taghi M, Sergent P, Liu WQ, Chhuon C, Vidal M, Picard M, Thioulouse E, Broutin I, Guerrera IC, Scherrmann JM, Parmentier Y, Decleves X, Menet MC.

J Neurochem. 2017 Aug;142(4):597-609. doi: 10.1111/jnc.14095. Epub 2017 Jul 11.

6.

Effect of Long-term In Vitro Lithium Exposure on mRNA Levels of Claudin-3, CYP1A1, ABCG2 and GSTM3 Genes in the hCMEC/D3 Human Brain Endothelial Cell Line.

Shawahna R, Ganeshamoorthy K, Huilong L, Scherrmann JM, Couraud PO, Declèves X.

Eur J Drug Metab Pharmacokinet. 2017 Dec;42(6):1013-1017. doi: 10.1007/s13318-017-0412-3.

PMID:
28367588
7.

The effect of morbid obesity on morphine glucuronidation.

Lloret-Linares C, Scherrmann JM, Declèves X.

Pharmacol Res. 2016 Dec;114:299-300. doi: 10.1016/j.phrs.2016.09.034. Epub 2016 Sep 28. No abstract available.

PMID:
27693275
8.

The effect of morbid obesity on morphine glucuronidation.

Lloret-Linares C, Luo H, Rouquette A, Labat L, Poitou C, Tordjman J, Bouillot JL, Mouly S, Scherrmann JM, Bergmann JF, Declèves X.

Pharmacol Res. 2017 Apr;118:64-70. doi: 10.1016/j.phrs.2016.08.031. Epub 2016 Sep 5.

PMID:
27609660
9.

Quantitative Atlas of Cytochrome P450, UDP-Glucuronosyltransferase, and Transporter Proteins in Jejunum of Morbidly Obese Subjects.

Miyauchi E, Tachikawa M, Declèves X, Uchida Y, Bouillot JL, Poitou C, Oppert JM, Mouly S, Bergmann JF, Terasaki T, Scherrmann JM, Lloret-Linares C.

Mol Pharm. 2016 Aug 1;13(8):2631-40. doi: 10.1021/acs.molpharmaceut.6b00085. Epub 2016 Jul 19.

PMID:
27347605
10.

Oral Morphine Pharmacokinetic in Obesity: The Role of P-Glycoprotein, MRP2, MRP3, UGT2B7, and CYP3A4 Jejunal Contents and Obesity-Associated Biomarkers.

Lloret-Linares C, Miyauchi E, Luo H, Labat L, Bouillot JL, Poitou C, Oppert JM, Laplanche JL, Mouly S, Scherrmann JM, Uchida Y, Tachikawa M, Terasaki T, Bergmann JF, Declèves X.

Mol Pharm. 2016 Mar 7;13(3):766-73. doi: 10.1021/acs.molpharmaceut.5b00656. Epub 2016 Jan 22.

PMID:
26751618
11.

Blood-brain and retinal barriers show dissimilar ABC transporter impacts and concealed effect of P-glycoprotein on a novel verapamil influx carrier.

Chapy H, Saubaméa B, Tournier N, Bourasset F, Behar-Cohen F, Declèves X, Scherrmann JM, Cisternino S.

Br J Pharmacol. 2016 Feb;173(3):497-510. doi: 10.1111/bph.13376. Epub 2016 Jan 15.

12.

Age-Dependent Regulation of the Blood-Brain Barrier Influx/Efflux Equilibrium of Amyloid-β Peptide in a Mouse Model of Alzheimer's Disease (3xTg-AD).

Do TM, Dodacki A, Alata W, Calon F, Nicolic S, Scherrmann JM, Farinotti R, Bourasset F.

J Alzheimers Dis. 2016;49(2):287-300. doi: 10.3233/JAD-150350.

PMID:
26484906
13.

Pharmacophore-based discovery of inhibitors of a novel drug/proton antiporter in human brain endothelial hCMEC/D3 cell line.

Chapy H, Goracci L, Vayer P, Parmentier Y, Carrupt PA, Declèves X, Scherrmann JM, Cisternino S, Cruciani G.

Br J Pharmacol. 2015 Oct;172(20):4888-904. doi: 10.1111/bph.13258. Epub 2015 Oct 13.

14.

A polyspecific drug/proton antiporter mediates diphenhydramine and clonidine transport at the mouse blood-retinal barrier.

Chapy H, André P, Declèves X, Scherrmann JM, Cisternino S.

Br J Pharmacol. 2015 Oct;172(19):4714-25. doi: 10.1111/bph.13246. Epub 2015 Aug 10.

15.

Aryl hydrocarbon receptor regulates CYP1B1 but not ABCB1 and ABCG2 in hCMEC/D3 human cerebral microvascular endothelial cells after TCDD exposure.

Jacob A, Potin S, Chapy H, Crete D, Glacial F, Ganeshamoorthy K, Couraud PO, Scherrmann JM, Declèves X.

Brain Res. 2015 Jul 10;1613:27-36. doi: 10.1016/j.brainres.2015.03.049. Epub 2015 Apr 7.

PMID:
25858487
16.

Influence of P-Glycoprotein Inhibition or Deficiency at the Blood-Brain Barrier on (18)F-2-Fluoro-2-Deoxy-D-glucose ( (18)F-FDG) Brain Kinetics.

Tournier N, Saba W, Goutal S, Gervais P, Valette H, Scherrmann JM, Bottlaender M, Cisternino S.

AAPS J. 2015 May;17(3):652-9. doi: 10.1208/s12248-015-9739-3. Epub 2015 Feb 26.

17.

Methadone dose in heroin-dependent patients: role of clinical factors, comedications, genetic polymorphisms and enzyme activity.

Mouly S, Bloch V, Peoc'h K, Houze P, Labat L, Ksouda K, Simoneau G, Declèves X, Bergmann JF, Scherrmann JM, Laplanche JL, Lepine JP, Vorspan F.

Br J Clin Pharmacol. 2015 Jun;79(6):967-77. doi: 10.1111/bcp.12576.

18.

Carrier-mediated cocaine transport at the blood-brain barrier as a putative mechanism in addiction liability.

Chapy H, Smirnova M, André P, Schlatter J, Chiadmi F, Couraud PO, Scherrmann JM, Declèves X, Cisternino S.

Int J Neuropsychopharmacol. 2014 Oct 31;18(1). pii: pyu001. doi: 10.1093/ijnp/pyu001.

19.

Hypoxia interferes with aryl hydrocarbon receptor pathway in hCMEC/D3 human cerebral microvascular endothelial cells.

Jacob A, Potin S, Saubaméa B, Crete D, Scherrmann JM, Curis E, Peyssonnaux C, Declèves X.

J Neurochem. 2015 Feb;132(4):373-83. doi: 10.1111/jnc.12972. Epub 2014 Nov 14.

20.

Effect of a Roux-en-Y gastric bypass on the pharmacokinetics of oral morphine using a population approach.

Lloret-Linares C, Hirt D, Bardin C, Bouillot JL, Oppert JM, Poitou C, Chast F, Mouly S, Scherrmann JM, Bergmann JF, Declèves X.

Clin Pharmacokinet. 2014 Oct;53(10):919-30. doi: 10.1007/s40262-014-0163-0.

PMID:
25141973
21.

Comparing translational population-PBPK modelling of brain microdialysis with bottom-up prediction of brain-to-plasma distribution in rat and human.

Ball K, Bouzom F, Scherrmann JM, Walther B, Declèves X.

Biopharm Drug Dispos. 2014 Nov;35(8):485-99. doi: 10.1002/bdd.1908. Epub 2014 Sep 17.

PMID:
25044007
22.

KCNH2 polymorphism and methadone dosage interact to enhance QT duration.

Hajj A, Ksouda K, Peoc'h K, Curis E, Messali A, Deveaux LL, Bloch V, Prince N, Mouly S, Scherrmann JM, Lépine JP, Laplanche JL, Drici MD, Vorspan F.

Drug Alcohol Depend. 2014 Aug 1;141:34-8. doi: 10.1016/j.drugalcdep.2014.04.027. Epub 2014 May 14.

PMID:
24875677
23.

Impact of P-glycoprotein at the blood-brain barrier on the uptake of heroin and its main metabolites: behavioral effects and consequences on the transcriptional responses and reinforcing properties.

Seleman M, Chapy H, Cisternino S, Courtin C, Smirnova M, Schlatter J, Chiadmi F, Scherrmann JM, Noble F, Marie-Claire C.

Psychopharmacology (Berl). 2014 Aug;231(16):3139-49. doi: 10.1007/s00213-014-3490-9. Epub 2014 Apr 5.

PMID:
24705903
24.

Altered cerebral vascular volumes and solute transport at the blood-brain barriers of two transgenic mouse models of Alzheimer's disease.

Do TM, Alata W, Dodacki A, Traversy MT, Chacun H, Pradier L, Scherrmann JM, Farinotti R, Calon F, Bourasset F.

Neuropharmacology. 2014 Jun;81:311-7. doi: 10.1016/j.neuropharm.2014.02.010. Epub 2014 Mar 12.

PMID:
24631967
25.

Pharmacokinetic simulations to explore dissolution criteria of BCS I and III biowaivers with and without MDR-1 efflux transporter.

Kortejärvi H, Malkki J, Shawahna R, Scherrmann JM, Urtti A, Yliperttula M.

Eur J Pharm Sci. 2014 Sep 30;61:18-26. doi: 10.1016/j.ejps.2014.02.004. Epub 2014 Feb 22. Erratum in: Eur J Pharm Sci. 2019 Apr 1;131:254.

PMID:
24566614
26.

A physiologically based modeling strategy during preclinical CNS drug development.

Ball K, Bouzom F, Scherrmann JM, Walther B, Declèves X.

Mol Pharm. 2014 Mar 3;11(3):836-48. doi: 10.1021/mp400533q. Epub 2014 Jan 29.

PMID:
24446829
27.

[¹¹C]befloxatone brain kinetics is not influenced by Bcrp function at the blood-brain barrier: a PET study using Bcrp TGEM knockout rats.

Hosten B, Boisgard R, Jacob A, Goutal S, Saubaméa B, Dollé F, Scherrmann JM, Cisternino S, Tournier N.

Eur J Pharm Sci. 2013 Nov 20;50(3-4):520-5. doi: 10.1016/j.ejps.2013.08.015. Epub 2013 Aug 24.

PMID:
23981334
28.

Effects of selected OATP and/or ABC transporter inhibitors on the brain and whole-body distribution of glyburide.

Tournier N, Saba W, Cisternino S, Peyronneau MA, Damont A, Goutal S, Dubois A, Dollé F, Scherrmann JM, Valette H, Kuhnast B, Bottlaender M.

AAPS J. 2013 Oct;15(4):1082-90. doi: 10.1208/s12248-013-9514-2. Epub 2013 Aug 2.

29.

Methodologies to assess drug permeation through the blood-brain barrier for pharmaceutical research.

Passeleu-Le Bourdonnec C, Carrupt PA, Scherrmann JM, Martel S.

Pharm Res. 2013 Nov;30(11):2729-56. doi: 10.1007/s11095-013-1119-z. Epub 2013 Jun 26. Review.

PMID:
23801086
30.

Human ABC transporters at blood-CNS interfaces as determinants of CNS drug penetration.

Chaves C, Shawahna R, Jacob A, Scherrmann JM, Declèves X.

Curr Pharm Des. 2014;20(10):1450-62. Review.

PMID:
23789951
31.

Physiologically based pharmacokinetic modelling of drug penetration across the blood-brain barrier--towards a mechanistic IVIVE-based approach.

Ball K, Bouzom F, Scherrmann JM, Walther B, Declèves X.

AAPS J. 2013 Oct;15(4):913-32. doi: 10.1208/s12248-013-9496-0. Epub 2013 Jun 20. Review.

32.

Oatp1a4 and an L-thyroxine-sensitive transporter mediate the mouse blood-brain barrier transport of amyloid-β peptide.

Do TM, Bedussi B, Chasseigneaux S, Dodacki A, Yapo C, Chacun H, Scherrmann JM, Farinotti R, Bourasset F.

J Alzheimers Dis. 2013;36(3):555-61. doi: 10.3233/JAD-121891.

PMID:
23635403
33.

Placental transfer of maraviroc in an ex vivo human cotyledon perfusion model and influence of ABC transporter expression.

Vinot C, Gavard L, Tréluyer JM, Manceau S, Courbon E, Scherrmann JM, Declèves X, Duro D, Peytavin G, Mandelbrot L, Giraud C.

Antimicrob Agents Chemother. 2013 Mar;57(3):1415-20. doi: 10.1128/AAC.01821-12. Epub 2013 Jan 7.

34.
35.

Coexistence of passive and proton antiporter-mediated processes in nicotine transport at the mouse blood-brain barrier.

Cisternino S, Chapy H, André P, Smirnova M, Debray M, Scherrmann JM.

AAPS J. 2013 Apr;15(2):299-307. doi: 10.1208/s12248-012-9434-6. Epub 2012 Dec 5.

36.

[Recent advances in quantitative proteomics as a sensitive tool to quantify drug transporters and drug metabolizing enzymes at the human blood-brain barrier].

Jacob A, Declèves X, Scherrmann JM.

Biol Aujourdhui. 2012;206(3):177-83. doi: 10.1051/jbio/2012022. Epub 2012 Nov 22. Review. French.

PMID:
23171840
37.

Quantitative targeted absolute proteomic analysis of transporters, receptors and junction proteins for validation of human cerebral microvascular endothelial cell line hCMEC/D3 as a human blood-brain barrier model.

Ohtsuki S, Ikeda C, Uchida Y, Sakamoto Y, Miller F, Glacial F, Decleves X, Scherrmann JM, Couraud PO, Kubo Y, Tachikawa M, Terasaki T.

Mol Pharm. 2013 Jan 7;10(1):289-96. doi: 10.1021/mp3004308. Epub 2012 Dec 11.

PMID:
23137377
38.

Respiratory toxicity of buprenorphine results from the blockage of P-glycoprotein-mediated efflux of norbuprenorphine at the blood-brain barrier in mice.

Alhaddad H, Cisternino S, Declèves X, Tournier N, Schlatter J, Chiadmi F, Risède P, Smirnova M, Besengez C, Scherrmann JM, Baud FJ, Mégarbane B.

Crit Care Med. 2012 Dec;40(12):3215-23. doi: 10.1097/CCM.0b013e318265680a.

PMID:
22975888
39.

ABC drug transporter and nuclear receptor expression in human cytotrophoblasts: influence of spontaneous syncytialization and induction by glucocorticoids.

Manceau S, Giraud C, Declèves X, Scherrmann JM, Artiguebieille F, Goffinet F, Chappuy H, Vinot C, Tréluyer JM.

Placenta. 2012 Nov;33(11):927-32. doi: 10.1016/j.placenta.2012.07.016. Epub 2012 Aug 24.

PMID:
22922069
41.

Transport of biogenic amine neurotransmitters at the mouse blood-retina and blood-brain barriers by uptake1 and uptake2.

André P, Saubaméa B, Cochois-Guégan V, Marie-Claire C, Cattelotte J, Smirnova M, Schinkel AH, Scherrmann JM, Cisternino S.

J Cereb Blood Flow Metab. 2012 Nov;32(11):1989-2001. doi: 10.1038/jcbfm.2012.109. Epub 2012 Aug 1.

42.

Induction of P-glycoprotein and Bcrp at the rat blood-brain barrier following a subchronic morphine treatment is mediated through NMDA/COX-2 activation.

Yousif S, Chaves C, Potin S, Margaill I, Scherrmann JM, Declèves X.

J Neurochem. 2012 Nov;123(4):491-503. doi: 10.1111/j.1471-4159.2012.07890.x. Epub 2012 Sep 3.

43.

Discrepancies in the P-glycoprotein-mediated transport of (18)F-MPPF: a pharmacokinetic study in mice and non-human primates.

Tournier N, Cisternino S, Peyronneau MA, Goutal S, Dolle F, Scherrmann JM, Bottlaender M, Saba W, Valette H.

Pharm Res. 2012 Sep;29(9):2468-76. doi: 10.1007/s11095-012-0776-7. Epub 2012 May 30.

PMID:
22644589
44.

Expression and induction by dexamethasone of ABC transporters and nuclear receptors in a human T-lymphocyte cell line.

Manceau S, Giraud C, Declèves X, Batteux F, Chéreau C, Chouzenoux S, Scherrmann JM, Weill B, Perrot JY, Tréluyer JM.

J Chemother. 2012 Feb;24(1):48-55. doi: 10.1179/1120009X12Z.00000000010.

PMID:
22546724
45.

[Stable iodine as a prophylaxis therapy following exposure to radioactive iodines: pharmacological and pharmaceutical characteristics].

Hosten B, Rizzo-Padoin N, Scherrmann JM, Bloch V.

Ann Pharm Fr. 2012 Mar;70(2):75-81. doi: 10.1016/j.pharma.2012.01.003. Epub 2012 Feb 28. Review. French.

PMID:
22500958
46.

ABCG2- and ABCG4-mediated efflux of amyloid-β peptide 1-40 at the mouse blood-brain barrier.

Do TM, Noel-Hudson MS, Ribes S, Besengez C, Smirnova M, Cisternino S, Buyse M, Calon F, Chimini G, Chacun H, Scherrmann JM, Farinotti R, Bourasset F.

J Alzheimers Dis. 2012;30(1):155-66. doi: 10.3233/JAD-2012-112189.

PMID:
22391220
47.

Aryl hydrocarbon receptor-dependent upregulation of Cyp1b1 by TCDD and diesel exhaust particles in rat brain microvessels.

Jacob A, Hartz AM, Potin S, Coumoul X, Yousif S, Scherrmann JM, Bauer B, Declèves X.

Fluids Barriers CNS. 2011 Aug 25;8:23. doi: 10.1186/2045-8118-8-23.

48.

Opioid transport by ATP-binding cassette transporters at the blood-brain barrier: implications for neuropsychopharmacology.

Tournier N, Declèves X, Saubaméa B, Scherrmann JM, Cisternino S.

Curr Pharm Des. 2011;17(26):2829-42. Review.

PMID:
21827411
49.

Heterogeneity in the rat brain vasculature revealed by quantitative confocal analysis of endothelial barrier antigen and P-glycoprotein expression.

Saubaméa B, Cochois-Guégan V, Cisternino S, Scherrmann JM.

J Cereb Blood Flow Metab. 2012 Jan;32(1):81-92. doi: 10.1038/jcbfm.2011.109. Epub 2011 Jul 27.

50.

Transcriptomic and quantitative proteomic analysis of transporters and drug metabolizing enzymes in freshly isolated human brain microvessels.

Shawahna R, Uchida Y, Declèves X, Ohtsuki S, Yousif S, Dauchy S, Jacob A, Chassoux F, Daumas-Duport C, Couraud PO, Terasaki T, Scherrmann JM.

Mol Pharm. 2011 Aug 1;8(4):1332-41. doi: 10.1021/mp200129p. Epub 2011 Jul 8.

PMID:
21707071

Supplemental Content

Loading ...
Support Center